{"id":"1f06534789ee","type":"article","url":"https://hartvaat.nl/2026/02/06/glp-1-receptoragonisten-en-nieruitkomsten-focus-op-albuminurie/","title":"GLP-1-receptoragonisten en nieruitkomsten: focus op albuminurie","title_en":"Glucagon-like Peptide Receptor Agonists and Kidney Outcomes in the Era of Personalized Medicine: Focus on Albuminuria.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","cardioloog","internist"],"tags":["cardiorenal-behandelstrategie","cystatine-c","glp1-agonisten","glp1-semaglutide-cardiovasculair","liraglutide","orforglipron","semaglutide","tirzepatide"],"journal":"Journal of personalized medicine","doi":"10.3390/jpm16020097","source_url":"https://doi.org/10.3390/jpm16020097","authors":["Ana Checa-Ros","Owahabanun Joshua Okojie","Jacob Gabriel Wassouf","Aida Yedean","Wei-Chung Hsueh","Patryk Hebda","Esther Rodriguez Llobell","Greta Bianca Muhmenthaler","Martin Duc-Duy Tran","Luis D'Marco"],"significance":6,"published":"2026-03-04","source_date":"2026-02-06","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/esc-richtlijn-diabetes-cvd-cardiometabool/","https://hartvaat.nl/kennis/nierziekte/sglt2-nierbescherming-mechanisme/"],"congress":"","summary_en":"This review assessed the renoprotective effects of GLP-1 receptor agonists with specific focus on albuminuria reduction, positioning these agents as important kidney-protective therapies alongside SGLT2 inhibitors in the personalized medicine era.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T13:31:27Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Dit review bespreekt de nierbeschermende effecten van GLP-1-receptoragonisten, met speciale aandacht voor het effect op albuminurie. In het tijdperk van gepersonaliseerde geneeskunde bieden deze middelen mogelijk aanvullende bescherming boven op SGLT2-remmers en RAS-blokkade, relevant voor de groeiende groep patiënten met cardiometabool-renale ziekte.","abstract_original":"The aim of this narrative review is to critically assess the renoprotective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in managing albuminuria among patients with type 2 diabetes mellitus within the framework of personalized medicine. By integrating current evidence from clinical trials and meta-analyses, the review highlights how GLP-1RAs not only enhance glycemic control but also reduce blood pressure, induce weight loss, and mitigate inflammatory responses. While these given factors may vary according to individual patient profiles, they also collectively contribute to slowing the progression of diabetic kidney disease (DKD). Additionally, the discussion emphasizes the dual cardiovascular and renal benefits from these agents, underscoring their role in reducing albuminuria and preserving renal function. The review also identifies gaps in knowledge, suggesting future research directions for optimizing patient selection and treatment regimens to maximize therapeutic benefits."}